10-Q: DLH Holdings Corp. Reports Second Quarter Results with Revenue Decline and Increased Tax Rate
Quarterly Report
DLH Holdings Corp. reported a slight decrease in revenue for the quarter ended June 30, 2024, alongside a notable increase in its effective tax rate.
Summary
- DLH Holdings Corp. reported a revenue of $100.7 million for the three months ended June 30, 2024, a slight decrease from $102.2 million in the same period last year.
- Net income for the quarter was $1.1 million, down from $1.7 million in the prior year.
- The company's effective tax rate increased to 29.7% for the quarter, compared to 20.6% in the same period last year.
- For the nine months ended June 30, 2024, revenue was $299.6 million, up from $274.4 million in the prior year.
- Net income for the nine-month period was $5.1 million, compared to $4.1 million in the prior year.
- The company's backlog was approximately $670.5 million as of June 30, 2024, down from $704.8 million at the end of September 2023.
- The company has a secured term loan of $152 million and a secured revolving line of credit of $14.5 million as of June 30, 2024.
Sentiment
Score: 5
Explanation: The document presents mixed results with a slight decrease in quarterly revenue and net income, but an increase in revenue and net income for the nine-month period. The decrease in backlog and increase in tax rate are negative factors, while the company's compliance with loan covenants and focus on growth are positive. Overall, the sentiment is neutral to slightly negative.
Positives
- Revenue for the nine months ended June 30, 2024, increased by $25.2 million compared to the same period in 2023.
- Net income for the nine-month period increased to $5.1 million, up from $4.1 million in the prior year.
- EBITDA for the nine months ended June 30, 2024, increased to $31.3 million, up from $28.2 million in the same period last year.
- The company made voluntary prepayments of $7.1 million on its secured term loan during the nine months ended June 30, 2024.
- The company is in compliance with all loan covenants and restrictions as of June 30, 2024.
Negatives
- Revenue for the three months ended June 30, 2024, decreased by $1.5 million compared to the same period in 2023.
- Net income for the quarter decreased to $1.1 million, down from $1.7 million in the prior year.
- The effective tax rate for the quarter increased to 29.7%, up from 20.6% in the same period last year.
- The company's backlog decreased to $670.5 million as of June 30, 2024, down from $704.8 million at the end of September 2023.
Risks
- The company is dependent on its relationships with major customers, and a loss of any of these customers could materially affect its financial condition.
- The company faces risks related to government contract procurement, including bid protests and small business set-asides.
- The company's ability to compete for prime contractor positions may be limited by set-aside provisions.
- The company's debt obligations could impact its financial flexibility.
- Changes in client budgetary priorities could affect the company's revenue.
- The company is exposed to the impact of inflation and higher interest rates.
Future Outlook
The company aims to expand its position as a trusted provider of technology-enabled healthcare and public health services, medical logistics, and readiness enhancement services. The company believes its business development priorities will position it to expand within top national priority programs and funded areas.
Management Comments
- The company is focused on delivering improved health and cyber readiness solutions for federal government customers.
- The company believes it is advantageously positioned within its markets due to its highly credentialed workforce, prime contractor status, strong past performance, and bipartisan support for key contracts.
- Management believes that its current investment and financing obligations are adequately covered by cash generated from profitable operations.
Industry Context
The company operates in the government contracting sector, providing services to various federal agencies. The company's performance is influenced by government spending, budgetary priorities, and procurement policies. The company faces competition from other government contractors, including small businesses that may have preferential treatment in certain contract awards.
Comparison to Industry Standards
- DLH's revenue mix of 55.1% time and materials, 24.7% firm fixed price, and 20.1% cost reimbursable contracts is typical for government contractors.
- The company's reliance on major customers such as the Department of Health and Human Services, Department of Veterans Affairs, and Department of Defense is common in the industry.
- The company's backlog of $670.5 million is a key indicator of future revenue, and the decrease from $704.8 million may be a concern for investors.
- The company's EBITDA of $31.3 million for the nine months ended June 30, 2024, is a measure of profitability that is often compared to industry peers.
- Companies like Leidos, CACI, and Booz Allen Hamilton are larger competitors in the government contracting space, and DLH's results should be viewed in comparison to their performance.
Stakeholder Impact
- Shareholders may be concerned about the decrease in quarterly revenue and net income, as well as the decrease in backlog.
- Employees may be affected by changes in contract awards and the company's overall financial performance.
- Customers may be impacted by the company's ability to continue providing services under existing contracts.
- Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.
Next Steps
- The company intends to submit revised proposals with its SDVOSB partner for the remaining CMOP locations.
- The company will continue to operate as the prime contractor for all CMOP locations other than the Chelmsford location while the acquisition process is being conducted.
- The company will continue to monitor the impact of federal contractual set-aside laws and regulations.
Key Dates
| Date | Description |
|---|---|
| January 31, 2023 | The company executed a floating-to-fixed interest rate swap with FNB. |
| December 6, 2023 | The company's Annual Report on Form 10-K for the year ended September 30, 2023 was filed with the Securities and Exchange Commission. |
| December 15, 2023 | Date of certain performance-based restricted stock unit grants. |
| January 27, 2023 | Date of certain performance-based restricted stock unit grants. |
| June 30, 2024 | End of the reporting period for the quarterly report. |
| July 30, 2024 | Date of the latest practicable date for the number of shares outstanding. |
| July 31, 2024 | Date of the report and certifications. |
Keywords
government contracts, healthcare, cybersecurity, digital transformation, public health, federal government, revenue, backlog, EBITDA, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.